New Products

CLOSTER, N.J. — If the Justin Bieber-inspired nail lacquer shades, One Less Lonely Girl, from Nicole by OPI are any indication of the success of Bieber-related 
products, then his upcoming women’s fragrance, “Someday,” is bound to spark Bieber fever.


The fragrance debuted in June in partnership with Give Back Brands, a new lifestyle products company committed to donating its proceeds to charity. The fragrance is hitting select specialty stores in June and reportedly will be priced between $35 and $55.


ABBOTT PARK, Ill. — The Food and Drug Administration has approved a new formulation of an injectable drug made by Abbott for prostate cancer.

Abbott announced Monday the approval of a 45-mg, six-month formulation of Lupron Depot (leuprolide acetate) for advanced prostate cancer. Previous formulations have allowed patients to receive the drug every month or every three or four months.

NEW YORK — ESI Cases and Accessories is encouraging consumers to get a whiff of the company's Jelly Belly candy-scented smartphone and accessories cases.

Through its new product catalog, the company unveiled accessories for iPhone, iPod, Blackberry and gaming devices that smell like Jelly Belly jelly bean candies. The gel cases are available in five scents, including Very Cherry, Licorice, Blueberry, Strawberry Cheesecake and Berry Blue.

TARRYTOWN, N.Y. — A panel of Food and Drug Administration experts has recommended approval of an investigational biotech drug made by Regeneron Pharmaceuticals for eye diseases.

Regeneron said Friday that the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee unanimously recommended approval of Eylea (aflibercept) ophthalmic solution for the treatment of a form of age-related macular degeneration, also known as wet AMD. The disease causes abnormal growth of new blood vessels in the eye.

NEW YORK — Hyland’s will attempt to parlay its success across its 4 Kids line of homeopathic solutions into the adult section with its recent launch of the Hyland’s Defend line. “We are seeing tremendous growth in our cold and cough 4 Kids,” noted Jay Borneman, chairman and CEO at Hyland’s. 


In the year leading up to the switch of Allegra, Sanofi generated $214.2 million in U.S. prescription sales of Allegra, largely due to the generic competition against its Allegra D formulation. Now Sanofi is looking to virtually match those annual sales figures within the much more profitable nonprescription venue with the company’s successful switch from prescription to OTC this spring. 


Couponing is digitizing.


Although printed circulars remain the workhorse of the nation’s coupon distribution system, a growing share of the coupons consumers are handing cashiers are emerging from online distribution sources and are being printed out at home. A smaller but growing segment also is being handled exclusively through electronic means via smartphones and mobile technology.


It’s like if KITT, the talking car on the 80s TV hit “Knight Rider,” consulted Hasselhoff about his excessive drinking while the two used advanced automotive and information-based technology to fight crime — and improve health outcomes.